Analysis of the Household and Health Care System Expenditures in Bulgaria

Zornitsa Mitkova* and Guenka Petrova

Department of Organization and Economy of Pharmacy, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria

Health care systems worldwide are experiencing tremendous financial pressure because of the introduction of new targeted health technologies and medicines. This study aims to analyze and compare public and household healthcare expenditures in Bulgaria during the period 2015–2019, as well as present the major cost-containment measures implied by the government and their probable influence on the overall health care cost. Regulatory analysis of the endorsed cost-containment measures, budget analysis of public and household health care expenditures, and their extrapolations were performed. The regulatory analysis reveals that a large number of measures are introduced and valid until January 2021, considering pharmaceuticals, medical devices, and negotiations between the National Health Insurance Fund (NHIF) and Marketing authorization holders (MAHs). NHIF costs due to pharmaceuticals, food supplements, and medical devices are rising from 2015 to 2019. The overall health expenditures average per household and the average per person also grow in this period. The cost extrapolation reveals that an increase in 3-year periods is expected. Despite the implementation of variety of cost-containment measures in Bulgaria, such as HTA, ERP, discounts, and annual negotiations, The National Health Insurance Fund’s (NHIF) spending on pharmaceuticals continues to rise in recent years, and further increases are expected in the next 3 years. The average expenditure per household and per person also increased, which confirms the global trend of rising medicine and outpatient services value.

Keywords: public expenditures, household expenditures, healthcare expenditure, cost containment measures, Bulgaria

INTRODUCTION

EU countries spent about 9.6% of their GDP on healthcare in 2017. Switzerland spent the largest share (12.3%), and Turkey the lowest with 4.2%. Among EU countries, Germany spent the most on pharmaceuticals per capita (EUR 572), whereas in Ireland it is EUR 498, and in Belgium it is EUR 491. These countries spent nearly 20% more than the average EU rate. In contrast, Denmark (EUR 203), Romania (EUR 255), Estonia (EUR 262), and Poland (EUR 267) spent less on pharmaceuticals per capita (1).

Despite the implementation of a variety of cost-containment measures worldwide, pharmaceutical expenditures continue to rise. Therefore, efficient allocation of a health care budget is especially important for ensuring adequate financing of hospital services, pharmaceuticals, and
physicians’ care. Pharmaceuticals’ expenditures capping is unlikely to affect resource allocation effectively (2). Despite some evidence from Germany, Portugal, Italy, and France, pharmaceutical expenditure capping and payback mechanisms might lead to cost savings (3).

Health care systems worldwide are experiencing tremendous financial pressure because of the introduction of new targeted health technologies and medicines. Insufficient financing might place a financial burden on households. Some studies show that the level of co-payment for health care services is exceedingly high in Bulgaria (4, 5). For medicines, it is almost 45% and creates a risk for patients’ non-compliance due to financial constraints of the families (6).

This study aims to analyze and compare public and household healthcare expenditures in Bulgaria during the period 2015–2019, as well as present the major cost-containment measures implied by the government and their probable influence on the overall health care cost.

MATERIALS AND METHODS

Design of the Study
Regulatory analysis of all cost-containment measures implemented in Bulgaria and endorsed until January 2021 in the first part of the study.

The next part of the study presents a comparative, retrospective, observational, and macroeconomic analysis of NHIF and household expenditure during the 2015–2019 periods. Both public and household expenditures are presented in terms of total and per capita. Extrapolation of expenditures is also applied to establish future tendencies.

All costs are presented in Euros based on the exchange rates of 1 Euro = 1.95 BGN in December 2021.

Data Sources
Two databases were analyzed in this study. The National Statistical Institute (NSI) database was used to extract household health care expenditures. They were categorized into the following groups as demonstrated in Table 1.

The dataset of the National Health Insurance Fund (NHIF) was reviewed to extract public expenditure on pharmaceuticals, medical devices, and dietetic foods during the observed period.

Regulatory Analysis
Cost-containment measures endorsed in the legislation until January 2021 and concerning payment of pharmaceuticals and health care services, as well as describing negotiations among main stakeholders (NHIF) and marketing authorization holders (MAHs) are systematized chronologically and explained.

Statistical Analysis
The t-test via Excel 10 was applied to establish statistically significant differences between all household costs during the observed period.

RESULTS

Cost-Containment Measures in Bulgaria
The cost-containment measures endorsed until January 2021 mainly cover NHIF expenditures for pharmaceuticals, medical devices, and dietetic food (Table 2). All measures were negotiated with MAHs and signed annually in an agreement.

Despite the permanent endorsement of new cost-containment measures in Bulgaria, the payers’ expenditure has continued to rise in recent years.

NHIF Expenditure
We found a slight cost increase during the 2015–2019 period (Table 3) considering the reimbursement of medicinal products, food supplements, and medical devices.

Further cost extrapolation reveals that the NHIF cost for medicinal products as well as overall costs, including medical devices and food supplements, is expected to rise within the next 3 years (Figure 1).

Household Expenditure
We found a slow increase in household expenditure until 2018, whereas in 2019, the increase was significant. Household expenditure in Bulgaria differs in recent years due to changes in prices and reimbursement medicines, outpatient clinical services, and hospital care. The cost could be observed from the individual person’s point of view as well as the average per household (Table 4).

The lowest growth is found in household costs related to outpatient services, general practices, and specialist practices covered by the NHIF. The highest growth was observed for hospital services and overall costs for medicinal products, appliances, and equipment.

Despite cost variations, the t-test confirms that statistically significant changes occurred between 2015 and 2019 and between 2018 and 2019 with regard to the average cost per person.

Further cost extrapolation reveals a rising tendency, except for the costs for outpatient services and specialist practices (Figures 2, 3).

The share of household healthcare expenditure is between 5.3 and 6.3% of all annual household expenditures.

DISCUSSION

Bulgaria spent EUR 1,311 per capita, or 8.1% of its GDP on health. Expenditures for pharmaceuticals are higher than
TABLE 2 | Cost containment measures available and actual in January 2021 in Bulgaria.

| Implemented measure | Brief explanation | Regulatory act |
|----------------------|-------------------|----------------|
| NHIF financial package includes dietetic foods; medical and dental prevention and diagnostics activities; urgent medical care; rehabilitation; pregnancy; childbirth, and maternity health care; outpatient medicinal products; medical devices and dietary foods; aids, devices, and facilities for people with disabilities. | According to law NHIF pays for dietetic food when they are reimbursed in at least three of the following countries: Romania, Czech Republic, Estonia, Greece, Hungary, Lithuania, Portugal, and Spain, as well as urgent, ambulatory treatment of all citizens. | Health Insurance Law, last amended December 2020 (7) |
| Price control based on international price referencing (external reference pricing) with 10 reference countries. Generics price capping and their link with the originator price. Relationship between price regulation and reimbursement policies. | The reference price setting was introduced for the first time in 2011 to control NHIF expenditure for all medicines on the positive drug list (PDL). Prices of generics or biosimilars should not exceed 70% of originators prices and 80% of reference biologic. A positive drug list is implemented during 2007 and reimbursement is based on the lowest price per DDD (internal reference pricing) for each individual INN. | Ordinance on rules, conditions, regulations and price registration of medicinal products, last amended March 2020 (6), Ordinance on rules, conditions, regulations and price registration of medicinal products, last amended March 2020 (6), Ordinance on rules, conditions, regulations and price registration of medicinal products, last amended March 2020 (6) |
| Annual negotiations and price-volume agreements concerning all reimbursed medicines included in PDL. Annual negotiations and price-volume agreements concerning all fully reimbursed medical devices for hospital care. HTA for new medicines before inclusion in PDL. | The mechanism is applied in case of exceeding of annual amount paid by National Health Insurance Fund for medicinal products. If their expenditures exceed the planned, MAH pay-backs the exceeded amount. Cap on sales volume was implemented in 2018 to reach budget sustainability and predictability. The mechanism is applied in case of exceeding of annual amount paid by National Health Insurance Fund for medical devices. Positive HTA evaluation of cost-effectiveness of new medicines is obligatory. | Ordinance on rules, conditions, regulations and price registration of medicinal products, last amended March 2020 (6), Ordinance on rules, conditions, regulations and price registration of medicinal products, last amended March 2020 (6), Health Insurance Law, last amended December 2020 (7) |
| Discount of medicinal products in a group where no generics are available for treatment of chronic and oncology diseases, as well as new INNs included in PDL. Discount concerning new medicinal products before inclusion in PDL based on agreement between MAH and NHIF. | Discount should be not <10% of reimbursed price for medicinal products for 3 months period. Annual discount is applied if there is an increase in forecasted expenditures negotiated between MAH and NHIF. The discount could be 25, 50, 75, 90% depending on exceeded amount annually. After positive HTA decision MAH and NHIF have to discuss the annual rate of discount which is obligatory. | Ordinance 10 on the conditions and procedures for medicinal products payment based on Law of medicinal products in human medicines, medical devices, and dietary foods, and specific activities regulated by Health Law, last amended November 2017 (9), Ordinance 10 on the conditions and procedures for medicinal products payment based on Law of medicinal products in human medicines, medical devices, and dietary foods, and specific activities regulated by Health Law, last amended November 2017 (9) |

TABLE 3 | NHIF expenditures during 2015–2019.

| NHIF expenditure, euro | 2015 | 2016 | 2017 | 2018 | 2019 |
|------------------------|------|------|------|------|------|
|                        | Total annual cost | Cost per patient | Total annual cost | Cost per patient | Total annual cost | Cost per patient | Total annual cost | Cost per patient | Total annual cost | Cost per patient |
| Pharmaceuticals        | 319,994,122.9 | 44.73 | 354,131,856 | 49.87 | 408,233,778 | 57.91 | 406,634,309 | 58.09 | 407,881,389 | 58.68 |
| Pharmaceuticals, food supplements, medical devices | 331,785,134.6 | 46.38 | 365,552,750 | 51.47 | 420,264,505 | 59.61 | 419,348,925 | 59.91 | 420,703,772 | 60.52 |
| Period considering for | 2015/2016 | 2016/2017 | 2017/2018 | 2018/2019 | 2015/2019 |
| Change in a %          | 10     | 14    | −0.22  | 0.31  | 27     |
the EU average and over 40% of the total health expenditure (10). Increases in income, improved household status, and affordability of medicines had a positive impact on private and public consumption growth (11).

Mediterranean countries spend less on healthcare than the EU average, both as a proportion of GDP and per capita. This is a result of lower than the EU average public funding of healthcare (12). Greece and Slovenia have the largest health care spending as percent of GDP in the period from 1995 to 2014, while the largest increase in health care expenditures was observed in Lithuania in 2014. The median value of out-of-pocket payment for health is the highest in Albania and
Our results indicate that household and public expenditures in Bulgaria rose during 2015–2019 and will continue to rise in the next 3 years. The highest is the increase in hospital services, medicinal products, appliances, and equipment.

Household and public expenditures vary significantly among EU countries. The UK study reveals that healthcare costs over 9 years (2008/09–2016/17) increased significantly. Expenditures for hospital care increased by 54.1%, corresponding to increases in both activity (29.2%) and cost (15.7%), whereas community prescription grew by 45.2%, with costs falling by 24.4% due to generic utilization and HTA implementation. Overall, it accounts for over one-fifth of the total expenditure in the English NHS (14).

The Greek household health expenditure rapidly increased during the period 1988–2008 and then started to decrease. The same tendency is observed for public expenditure, household medical services, and pharmaceuticals (15).

During the period 2004–2015, the share of health expenditure as a part of the total household expenditures in Estonia, Lithuania, and Latvia remained almost stable; however, the share of health care expenditures of Polish households had increased. Compared to 2004, in 2015, Estonian, Latvian, and Lithuanian households spent less on medicinal products, appliances, and equipment, and more on outpatient services (16).

According to our results, NHIF expenditures in Bulgaria rose by 27% during 2015–2019, while household expenditures increased mainly in 2019. Within the period 2015–2019, their increase is significant, especially those for hospital treatments.
Most out-of-pocket expenditures in Albania included medicines and medical devices, followed by diagnostic and outpatient services. Hospital services and treatment abroad are less frequent but costly (17).

Different factors influence medicine prices and public expenditure worldwide. ERP is not an effective price control measure. If this methodology is implemented with minimal price revisions and a selection of basket size and countries with similar development, it could be more effective and could help ensure innovation incentives for the industry (18).

When the growth of pharmaceutical spending in France stopped, access to innovative medicines improved. The added therapeutic value of new medicines is a major reason for the reimbursement of new medicines, and institutions pay more for superior medicinal products. MAHs pay claw backs when expenditures exceed the budget, as approved by Parliament (19).

HTA and economic evaluation could lead to more rational evidence-based decision-making, possibly improving efficiency in resource allocation (20).

Despite the implementation of cost-containment measures in Bulgaria, using HTA, ERP, discount, and annual negotiations, pharmaceutical spending continued to rise recently, considering both NHIF and household points of view. Therefore, the introduction of new approaches is needed to stop and effectively control the increasing costs in a country.

The limitation of this study is the lack of data for all groups’ NHIF expenditure, thus limiting the analysis only to reimbursed expenditures for pharmaceuticals, food supplements, and medical devices.

CONCLUSION

Despite the implementation of a variety of cost-containment measures in Bulgaria, such as HTA, ERP, discounts, and annual negotiations, NHIF spending on pharmaceuticals has continued to rise in recent years, and further increases are expected in the next 3 years.

The average expenditure per household and per person also increased, which confirms the global trend of rising medicines and outpatient services value.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

AUTHOR CONTRIBUTIONS

GP conceived and designed the investigation and wrote the discussion and conclusion. ZM collected the data and performed the data analysis and results section. All authors wrote and revised the manuscript and approved its submission for publication, confirming that the work is original.

FUNDING

This study was part of the National Scientific Program Electronic healthcare in Bulgaria (E-health), supported by the Ministry of Education and Science.

REFERENCES

1. OECD/European Union. “Health Expenditure in Relation to GDP”. Health at a Glance: Europe. Paris: OECD Publishing/Brussels: European Union (2018): State of Health in the EU Cycle (2018).
2. Kanavos P, Mills M, Cheatley J, Lopez-Casassovas G, Manganeli A, Maynou L, et al. Controlling Expenditure Within the Spanish Pharmaceutical Market: Macro- and Micro-Level Policy Approaches. London, UK: LSE Health (2017).
3. Espin J, Rovira J. Analysis of Differences and Commonalities in Pricing and Reimbursement Systems in Europe. DG Enterprise and Industry. European Commission (2007). Available online at: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/study_pricing_2007/andalusian_school_public_health_report_pricing_2007_en.pdf (accessed June 19, 2021).
4. Atanasonova E, Pavlova M, Moutafova E, Rechel B, Groot W. Informal payments for health services: the experience of Bulgaria after 10 years of formal co-payments. Eur J Public Health. (2014) 24:733–9. doi:10.1093/europub/ckt165
5. Dimova A, Rohova M, Atanasonova E, Kavalec P, Czok K. Drug policy in Bulgaria. Value Health Reg Issues. (2017) 13:50–4. doi:10.1016/j.vhri.2017.08.001
6. Chan AHY, Cooper V, Lycett H, Horne R. Practical barriers to medication adherence: what do current self- or observer-reported instrument assess? Front Pharmacol. (2020) 11:572. doi:10.3389/fphar.2020.00572
7. Health Insurance Law, St gazette 70 From 19.06.1998; Amended and Supplemented Gov. Newsp. 105 (December) (2020). Available online at: https://www.nssi.bg/legislationbg/laws/271-xzo (accessed June 19, 2021).
8. Ministry of Health. Ordinance on the Terms, Rules and Procedure for Regulation and Registration of Prices for Medicinal Products. (2020). amended and supplemented Gov. Newsp. Available online at: http://www.ncpr.bg (accessed April 30, 2013).
9. Ministry of Health. Regulation Amended and Supplemented Ordinance? 10 of 2009 on the Conditions, Procedure, Mechanism and Criteria for Payment by the National Health Insurance Fund of Medicinal Products, Medical Devices and Dietary Foods for Special Medical Purposes, Gov. Newsp. 89 November. Ministry of Health. Sofia: Bulgaria (2017).
10. State of health in the EU Bulgaria. Country Health Profile. (2019). Available online at: http://oeecd.org/health-health-systems/country-health-profiles-EU.htm (accessed June 19, 2021)
11. Country report Bulgaria (2018). Including an In-Depth Review on the prevention correction of macroeconomic imbalances 2018 European Semester: Assessment of progress on structural reforms, prevention correction of macroeconomic imbalances, results of in-depth reviews under Regulation (EU) No 1176/2011. Brussels, 7.3.2018 SWD. Final. 201 (2018).
12. Grima S, Spiteri JV, Jakovljevic M, Camilleri C, Buttigieg SC. High out-of-pocket health spending in countries with a Mediterranean connection. Front Public Health. (2018) 6:145. doi:10.3389/fpubh.2018.00145
13. Stepovic M, Rancic N, Vekic B, Dragojevic-Simic V, Vekic S, Ratkovic N, et al. Gross domestic product and health expenditure growth in Balkan and east European countries-three-decade horizon. Front Public Health. (2020) 8:492. doi:10.3389/fpubh.2020.00492
14. Rodriguez Santana I, Aragón MI, Rice N, Mason AR. Trends in and drivers of healthcare expenditure in the English NHS: a retrospective analysis. Health Econ Rev. (2020) 10:20. doi: 10.1186/s13561-020-00278-9
15. Zikidou S, Hadjidema S. Households health expenditure in inter annual correlation with public health expenditure in Greece. Front Public Health. (2020) 8:448. doi:10.3389/fpubh.2020.00448
16. Walczak R, Pieikut M, Kludaæ-Alessandi MA, Sloka B, Šimanskïene L, Paas T. Health care spending structures in Poland, Latvia, Lithuania and Estonia
over the years as compared to other EU countries. Found Manag. (2018) 10:45–58. doi: 10.2478/fman-2018-0005

17. Arenliu Qosaj F, Froeschl G, Berisha M, Bellaqa B, Holle R. Catastrophic expenditures and impoverishment due to out-of-pocket health payments in Kosovo. Cost Eff Resour Alloc. (2018) 16:26. doi: 10.1186/s12962-018-0111-1

18. Kanavos P, Fontrier AM, Gill J, Efthymiadou O. Does external reference pricing deliver what it promises? Evidence on its impact at national level. Eur J Health Econ. (2020) 21:129–51. doi: 10.1007/s10198-019-01116-4

19. Rodwin MA. Pharmaceutical price and spending controls in France: lessons for the United States. Int J Health Serv. (2020) 50:156–65. doi: 10.1177/0020731419897580

20. Angelis A, Lange A, Kanavos P. Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries. Eur J Health Econ. (2018) 19:123–52. doi: 10.1007/s10198-017-0871-0

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Mitkova and Petrova. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.